Liang Xin-Xin, Zhang Xing-Jie, Zhao Ying-Xin, Feng Jian, Zeng Jie-Chun, Shi Qiang-Qiang, Kaunda Joseph Sakah, Li Xiao-Li, Wang Wei-Guang, Xiao Wei-Lie
Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Provincial Center for Research & Development of Natural Products; School of Chemical Science and Technology, Yunnan University, Kunming 650091, People's Republic of China.
Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission and Ministry of Education and Key Laboratory of Natural Products Synthetic Biology of Ethnic Medicinal Endophytes, State Ethnic Affairs Commission, Yunnan Minzu University, Kunming 650031, People's Republic of China.
J Nat Prod. 2022 Apr 22;85(4):878-887. doi: 10.1021/acs.jnatprod.1c01003. Epub 2022 Mar 16.
Eight new aspulvinone analogues, aspulvins A-H (-) and aspulvinones D, M, O, and R (-), were isolated from cultures of the endophytic fungus sp. 7951. Detailed spectroscopic analyses were conducted to determine the structures of the new compounds. All isolates displayed different degrees of inhibitory activity against the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M) at 10 μM. Notably, compounds , , and showed potential SARS-CoV-2 M inhibition with IC values of 10.3 ± 0.6, 9.4 ± 0.6, and 7.7 ± 0.6 μM, respectively. For all compounds except and , the anti-inflammatory activity occurred by inhibiting the release of lactate dehydrogenase (LDH) with IC values ranging from 0.7 to 7.4 μM. Compound showed the most potent anti-inflammatory activity by inhibiting Casp-1 cleavage, IL-1β maturation, NLRP3 inflammasome activation, and pyroptosis. The findings reveal that the aspulvinone analogues , , and could be promising candidates for coronavirus disease 2019 (COVID-19) treatment as they inhibit SARS-CoV-2 infection and reduce inflammatory reactions caused by SARS-CoV-2.
从内生真菌sp. 7951的培养物中分离出8种新的aspulvinone类似物,即aspulvins A - H (-)以及aspulvinones D、M、O和R (-)。进行了详细的光谱分析以确定新化合物的结构。所有分离物在10 μM浓度下对严重急性呼吸综合征冠状病毒2主要蛋白酶(SARS-CoV-2 M)均表现出不同程度的抑制活性。值得注意的是,化合物、和对SARS-CoV-2 M显示出潜在抑制作用,其IC值分别为10.3±0.6、9.4±0.6和7.7±0.6 μM。对于除和之外的所有化合物,其抗炎活性是通过抑制乳酸脱氢酶(LDH)的释放实现的,IC值范围为0.7至7.4 μM。化合物通过抑制Casp-1裂解、IL-1β成熟、NLRP3炎性小体激活和细胞焦亡表现出最有效的抗炎活性。研究结果表明,aspulvinone类似物、和有望成为治疗2019冠状病毒病(COVID-19)的候选药物,因为它们能抑制SARS-CoV-2感染并减轻由SARS-CoV-2引起的炎症反应。